1. CV Risk Management in T2DM: What Did We Learn From EASD 2016?

2. Program Overview

3. EMPA-REG OUTCOME: Trial Design

4. EMPA-REG OUTCOME: Primary Endpoint: 3-Point MACE*

5. EMPA-REG OUTCOME: CV Death

6. EMPA-REG OUTCOME: CV Death, Nonfatal MI, and Nonfatal Stroke

7. EMPA-REG OUTCOME: All-Cause Mortality

8. EMPA-REG OUCTOME: Effect of Empagliflozin on CV Death in Subgroups by Age

9. Effect of Empagliflozin on HF Outcomes: Time to First Hospitalization for HF or CV Death

10. Effect of Empagliflozin on HF Outcomes: Outcomes in Patients With and Without HF At Baseline

11. EMPA-REG OUTCOME: Incident or Worsening Nephropathy

12. EMPA-REG OUTCOME: Risk Comparison for Renal Outcomes

13. Mechanistic Possibilities for the Beneficial CV Effects Observed in EMPA-REG OUTCOME Trial

14. Possible Mechanisms for the Effect of Empagliflozin on Reduced CV Risk

15. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis

16. Mechanistic Possibilities for the Beneficial CV Effects Observed in EMPA-REG OUTCOME Trial (cont)

17. LEADER: Study Design

18. LEADER: Primary Outcome*

19. LEADER: CV Death

20. LEADER: All-cause Death

21. SUSTAIN 6: Study Design

22. SUSTAIN-6: Primary Efficacy Outcome*

23. SUSTAIN-6: CV Endpoints

24. SUSTAIN-6: CV Endpoints (cont)

25. SUSTAIN-6, LEADER, and EMPA-REG OUTCOME: Similarities and Differences*

26. Duration of Action of GLP-1 RAs

27. Potential Mechanisms of Beneficial CV Effect of GLP-1 RAs: Many Possibilities Beyond Glucose Control

28. SUSTAIN-6 and LEADER: Is Diabetic Retinopathy a Potential Concern?

29. Conclusions

30. Conclusions (cont)

31. Abbreviations

32. Abbreviations (cont)